Not found

Bhuvanesh Dave, PhD

Assistant Research Professor of Oncology, Institute for Academic Medicine
Assistant Research Member, Research Institute
Houston Methodist


Biography

Dr. Bhuvanesh Dave earned his Ph.D. in Biochemistry and Molecular Biology from the University of Arkansas for Medical Sciences, Little Rock, AR, in 2005. He received postdoctoral training in the Arkansas Children’s hospital where he worked on the role of soy and whey proteins in the prevention of breast cancer, focusing on the role of PTEN in the mechanism of prevention. He continued his training with mouse models of cancer at the MD Anderson Cancer Center and completed his training at the Baylor College of Medicine, identifying key molecular targets for breast cancer treatment.  Dr. Bhuvanesh Dave is an Assistant Member of The Methodist Hospital Research Institute Cancer Research Program, and directs a research focusing on the role of autophagy in breast and pancreatic cancer survivorship. His additional area of interest is siRNA targeting of  breast cancer tumor initiating cells. Dr. Dave has served as an editor of the International Journal of Breast Cancer since 2010 and is an invited reviewer for multiple journals.

Description of Research

Dr. Dave's research focuses on targeting self-renewal pathways of tumor initiating cells in pancreatic and breast cancer. His lab studies the biology of tumor initiating cells and is developing new cancer therapies based on the understanding of tumor initiating cells using human cancer in mouse models as preclinical models. Current studies focus on the roles of autophagy and hypoxia in the survival of tumor initiating cells.

Areas Of Expertise

Cancer Stem cells Tumor initiation Autophagy High throughput
Education & Training

, Arkansas Children's Hospital
, Baylor College of Medicine
, GND University, Amritsar, India
, University of Arkansas for Medical Sciences
, University of Texas MD Anderson Cancer Center
Publications

Role of RPL39 in Metaplastic Breast Cancer
Dave, B, Gonzalez, DD, Liu, Z-B, Li, X, Wong, H, Granados, S, Ezzedine, NE, Sieglaff, DH, Ensor, Jr. JE, Miller, KD, Radovich, M, KarinaEtrovic, A, Gross, SS, Elemento, O, Mills, GB, Gilcrease, MZ & Chang, JC 2017, Journal of the National Cancer Institute, vol 109, no. 6. DOI:

Breast cancer cells form primary tumors on ex vivo four-dimensional lung model
Pence, KA, Mishra, DK, Thrall, M, Dave, B & Kim, MP 2017, Journal of Surgical Research, vol 210, pp. 181-187. DOI:

The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors
Phan, AT & Dave, B 2016, Cancer Medicine, vol 5, no. 10, pp. 2953-2964. DOI:

The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs
Norvaisas, P, Chan, D, Yokoi, K, Dave, B & Ziemys, A 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), vol 25, no. 1, pp. 77-84. DOI:

The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs
Norvaisas, P, Chan, D, Yokoi, K, Dave, B & Ziemys, A 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), vol 25, no. 1, pp. 77-84.

Autophagy Inhibition to Increase Radiosensitization in Breast Cancer
Liang, DH, El-Zein, R & Dave, B 2015, Journal of nuclear medicine & radiation therapy, vol 6, no. 5. DOI:

Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer
Young, CD, Zimmerman, LJ, Hoshino, D, Formisano, L, Hanker, AB, Gatza, ML, Morrison, MM, Moore, PD, Whitwell, CA, Dave, B, Stricker, T, Bhola, NE, Silva, GO, Patel, P, Brantley-Sieders, DM, Levin, M, Horiates, M, Palma, NA, Wang, K, Stephens, PJ, Perou, CM, Weaver, AM, OShaughnessy, JA, Chang, JC, Park, BH, Liebler, DC, Cook, RS & Arteaga, CL 2015, Molecular and Cellular Proteomics, vol 14, no. 7, pp. 1959-1976. DOI:

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
Bharadwaj, U, Eckols, TK, Kolosov, M, Kasembeli, MM, Adam, A, Torres, D, Zhang, X, Dobrolecki, LE, Wei, W, Lewis, MT, Dave, B, Chang, JC, Landis, MD, Creighton, CJ, Mancini, MA & Tweardy, DJ 2015, Oncogene, vol 34, no. 11, pp. 1341-1353. DOI:

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
Granados-Principal, S, Liu, Y, Guevara, ML, Blanco, E, Choi, DS, Qian, W, Patel, T, Rodriguez, AA, Cusimano, J, Weiss, HL, Zhao, H, Landis, MD, Dave, B, Gross, SS & Chang, JC 2015, Breast Cancer Research, vol 17, no. 1, 25. DOI:

Erratum: Dual HER2 blockade: Preclinical and clinical data
Patel, TA , Dave, B , Rodriguez, AA , Chang, JC, Perez, EA & Colon-Otero, G 2014, Breast Cancer Research. DOI:

Dual HER2 blockade: Preclinical and clinical data
Patel, TA , Dave, B , Rodriguez, AA , Chang, JC, Perez, EA & Colon-Otero, G 2014, Breast Cancer Research, vol 16, no. 4, 419. DOI:

Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells
Jaganathan, H, Mitra, S, Srinivasan, S, Dave, B & Godin, B 2014, PLoS ONE, vol 9, no. 4, e91986. DOI:

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
Bharadwaj, U, Eckols, TK, Kolosov, M, Kasembeli, MM, Adam, A, Torres, D, Zhang, X, Dobrolecki, LE, Wei, W, Lewis, MT, Dave, B, Chang, JC, Landis, MD, Creighton, CJ, Mancini, MA & Tweardy, DJ 2014, Oncogene, vol 0. DOI:

Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation
Jaganathan, H, Gage, J, Leonard, F, Srinivasan, S, Souza, GR, Dave, B & Godin, B 2014, Scientific Reports, vol 4, 6468. DOI:

Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling
Dave, B, Granados-Principal, S, Zhu, R, Benz, S, Rabizadeh, S, Soon-Shiong, P, Yu, KD, Shao, Z, Li, X, Gilcrease, M, Lai, Z, Chen, Y, Huang, THM, Shen, H, Liu, X, Ferrari, M, Zhan, M, Wong, STC, Kumaraswami, M, Mittal, V, Chen, X, Gross, SS & Chang, JC 2014, Proceedings of the National Academy of Sciences of the United States of America, vol 111, no. 24, pp. 8838-8843. DOI:

Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1
Choi, DS, Blanco, E, Kim, YS, Rodriguez, AA, Zhao, H, Huang, THM, Chen, CL, Jin, G, Landis, MD, Burey, LA, Qian, W, Granados, SM, Dave, B, Wong, HH, Ferrari, M, Wong, STC & Chang, JC 2014, Stem Cells, vol 32, no. 9, pp. 2309-2323. DOI:

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors
Chakrabarty, A, Bhola, NE, Sutton, C, Ghosh, R, Kuba, MG, Dave, B, Chang, JC & Arteaga, CL 2013, Cancer Research, vol 73, no. 3, pp. 1190-1200. DOI:

The soybean peptide lunasin promotes apoptosis of mammary epithelial cells via induction of tumor suppressor PTEN: Similarities and distinct actions from soy isoflavone genistein
Pabona, JMP, Dave, B, Su, Y, Montales, MTE, De Lumen, BO, De Mejia, EG, Rahal, OM & Simmen, RCM 2013, Genes and Nutrition, vol 8, no. 1, pp. 79-90. DOI:

Modeling the tumor microenvironment as a biobarrier in cancer nanotherapeutics
Frieboes, HB, Yokoi, K, Dave, B, Hussain, F & Godin, B 2012, . in Mass Transport of Nanocarriers. Pan Stanford Publishing Pte. Ltd. pp. 137-183. DOI:

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance.
Dave, B , Mittal, V, Tan, NM & Chang, JC 2012, Breast cancer research : BCR, vol 14, no. 1.